Convenient Biological Assay for Polyethylene Glycol-Interferons in Patients with Hepatitis C-Reference-Cited by-同舟云学术

Convenient Biological Assay for Polyethylene Glycol-Interferons in Patients with Hepatitis C

Published:2004-09 Issue:9 Volume:48 Page:3610-3612
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Boulestin Anne¹,Kamar Nassim²,Legrand-Abravanel Florence¹,Sandres-Saune Karine¹,Alric Laurent³,Vinel Jean-Pierre⁴,Rostaing Lionel²,Izopet Jacques¹

Affiliation:

1. Laboratoire de Virologie EA 2046-IFR 30

2. Unité de Transplantation d'Organes, CHU RANGUEIL, Toulouse, France

3. Service de Médecine Interne

4. Service d'Hépato-Gastro-Entérologie, CHU PURPAN

Abstract

ABSTRACT The vesicular stomatitis virus cytopathic effect reduction assay is suitable to quantify polyethylene glycol-alpha interferon 2a (PEG-IFN-α2a) and PEG-IFN-α2b. Human serum and ribavirin did not interfere with the assay. This bioassay was successfully used for assaying PEG-IFN-α2a and PEG-IFN-α2b in serum samples from patients undergoing combination therapy.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.48.9.3610-3612.2004

Reference12 articles.

1. Boulestin, A., K. Sandres-Saune, J. L. Payen, L. Rostaing, C. Pasquier, and J. Izopet. 2003. Genetic heterogeneity of the NS5A gene of hepatitis C Virus and early response to interferon-alpha. J. Infect. Dis.188:1367-1370.

2. Chatelut, E., L. Rostaing, N. Gregoire, J. L. Payen, A. Pujol, J. Izopet, G. Houin, and P. Canal. 1999. A pharmacokinetic model for alpha interferon administered subcutaneously. Br. J. Clin. Pharmacol.47:365-371.

3. Glue, P., J. W. Fang, R. Rouzier-Panis, C. Raffanel, R. Sabo, S. K. Gupta, M. Salfi, and S. Jacobs. 2000. Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin. Pharmacol. Ther.68:556-567.

4. Izopet, J., J. L. Payen, L. Alric, K. Sandres, J. P. Charlet, J. P. Vinel, M. Duffaut, J. P. Pascal, and J. Puel. 1998. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy. J. Med. Virol.54:86-91.

5. Ribavirin Quantification in Combination Treatment of Chronic Hepatitis C

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients;Antimicrobial Agents and Chemotherapy;2014-06-30

2. Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy;Journal of Medical Virology;2011-01-24

3. Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV;Journal of Medical Virology;2008-09

4. Pegylation of IFN-α and Antiviral Activity;Journal of Interferon & Cytokine Research;2006-12

5. Quantification of Different Human Alpha Interferon Subtypes and Pegylated Interferon Activities by Measuring MxA Promoter Activation;Antimicrobial Agents and Chemotherapy;2005-09